Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22181109 | 0.97 | PSMB8 (0.32) | PSMB8ALDH1A1HSD11B1EPHX2 | |
| SCHEMBL20801502 | 0.97 | PSMB8 (0.32) | PSMB8ALDH1A1HSD11B1EPHX2 | |
| SCHEMBL24859939 | 0.97 | PSMB8 (0.32) | PSMB8ALDH1A1HSD11B1EPHX2 | |
| SCHEMBL20801415 | 0.85 | PSMB8 (0.39) | PSMB8ALDH1A1HSD11B1 | |
| SCHEMBL20801582 | 0.81 | — | — | |
| SCHEMBL24859936 | 0.79 | — | — | |
| SCHEMBL20801501 | 0.79 | — | — | |
| SCHEMBL24859925 | 0.79 | NAAA (0.37) | PSMB8ALDH1A1HSD11B1EPHX2 | |
| SCHEMBL22181082 | 0.79 | NAAA (0.37) | PSMB8ALDH1A1HSD11B1EPHX2 | |
| SCHEMBL12568580 | 0.77 | RECQL (0.33) | ALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11547761-B1 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210284750-A1 | Immunoconjugate Synthesis Method | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-09-16 | — | — | US | disclosed |
| US-11110178-B2 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200206357-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-10675358-B2 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206357-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | PSMB8 2177/4885ALDH1A1 978/4885HSD11B1 2578/4885 |
| US-10675358-B2 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | PSMB8 2177/4885ALDH1A1 978/4885HSD11B1 2578/4885 |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | PSMB8 2216/4885ALDH1A1 954/4885HSD11B1 2488/4885 |
| US-20210284750-A1 | Immunoconjugate Synthesis Method | FCGR3B, FCGR1A, FCGR2A | PSMB8 1203/4885ALDH1A1 3152/4885HSD11B1 2597/4885 |
| US-11547761-B1 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | PSMB8 2177/4885ALDH1A1 978/4885HSD11B1 2578/4885 |
| US-11110178-B2 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | PSMB8 2177/4885ALDH1A1 978/4885HSD11B1 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.